Cantor Fitzgerald analyst Louise Chen lowered her price target for Aerie Pharmaceuticals to $30 from $62 saying the company missed on earnings and lowered its 2019 sales guidance for the second quarter in a row. The analyst, however, keeps an Overweight rating on the shares because she thinks Aerie can successfully execute its strategy to become a leading ophthalmic pharmaceutical company focused on glaucoma, the retina, and dry eye.The peak sales potential of Rocklatan as well as Rhopressa and its pipeline is underappreciated by the Street, says Chen.